Gonalef filed for female infertility in Japan
This article was originally published in Scrip
Merck Seronohas submitted an approval application in Japan for the recombinant human follicle-stimulating hormone product Gonalef (follitropin alfa) for the additional indication of induction of ovulation in infertile women. The filing includes data from a local Phase III study in women with no or irregular ovulation or polycystic ovary syndrome. Gonalef (also marketed elsewhere as Gonal-f) was first launched in Japan in 2006 for infertility in men with hypogonadotropic hypogonadism, for which it is used in combination with human chorionic gonadotropin.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.